Drug intelligence / Profile preview

ΣΦ-1402

Development stage: Preclinical
Lead developer: Sigmapharm Laboratories
Modality: Small Molecules
Administration: Oral

Overview

ΣΦ-1402 is an internal development code for a pharmaceutical candidate within the pipeline of Sigmapharm Laboratories. Sigmapharm is a specialty pharmaceutical company that focuses on the development and manufacturing of complex generic and branded products, particularly those involving significant technical barriers such as formulation challenges, bioavailability issues, or patent litigation. ΣΦ-1402 is categorized as a product prepared for Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) submission. As of the most recent public disclosures, the specific chemical identity, therapeutic indication, and molecular target of ΣΦ-1402 remain proprietary and have not been released to the public.

Other names: Sigma-Phi-1402Sigma-Phi1402Sigma-Phi 1402

Beyond the preview

Go deeper on ΣΦ-1402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ΣΦ-1402.

Explore the full profile